Intravenous immunoglobulin

Current Allergy and Clinical Immunology

Volumn 21, Issue 1, 2008, Pages 26-31

  Goddard, E A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPHENHYDRAMINE; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN; PARACETAMOL;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; BACTERIAL INFECTION; CHILL; CHORIORETINOPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CORONARY ARTERY ANEURYSM; CORONARY ARTERY THROMBOSIS; DERMATOMYOSITIS; DISEASE COURSE; DRUG DOSE TITRATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; EATON LAMBERT SYNDROME; ECZEMA; ERYTHEMA MULTIFORME; EVIDENCE BASED MEDICINE; GUILLAIN BARRE SYNDROME; HEMOLYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; LIVER FUNCTION TEST; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; MYALGIA; MYASTHENIA GRAVIS; MYELOMA; MYOSITIS; NAUSEA; NERVE DEGENERATION; NEUTROPENIA; NOTE; OCCLUSIVE CEREBROVASCULAR DISEASE; PEMPHIGOID; PNEUMONIA; PRACTICE GUIDELINE; PROPHYLAXIS; PYODERMA GANGRENOSUM; RECURRENT INFECTION; RHINITIS; SCLEROMYXEDEMA; STIFF MAN SYNDROME; SUBSTITUTION THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; TOXIC SHOCK SYNDROME; TREATMENT INDICATION; URTICARIA; UVEITIS; VASCULITIS;

EID: 69949126082     PISSN: 16093607     EISSN: 16093607     Source Type: Journal    
DOI: None     Document Type: Note

References (28)

1. Constantine MM, Thomas W, Whitman L, et al. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion 2007; 47: 2072-2080. (Pubitemid 47623964)
2. Bruton OC. Agammaglobulinaemia. Pediatrics 1952; 9: 722-728.
3. Chapel HM. Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. Clin Exp Immunol 1999; 118: S29-S34.
4. World Health Organization. Appropriate uses of human immunoglobulin in clinical practice: Memorandum from an IUIS/WHO meeting. WHO Bulletin 1982: 60; 43-47.
5. Ballow M. Mechanisms of action of intravenous immune serum globulin therapy. Pediatr Infect Dis J 1994; 13: 806-811. (Pubitemid 24286818)
6. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142: 1-11.
7. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary Immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117: S525-S553.
8. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007; 21: S9-S56. (Pubitemid 46505088)
9. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune lobulin for neurologic conditions. Transfus Med Rev 2007; 21: S57-S107. (Pubitemid 46509469)
10. Robinson P, Andersen D, Brouwers M, et al. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 2007; 21: S3-S8. (Pubitemid 46482994)
11. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Paediatr Infect Dis 1997; 16: 696-707.
12. Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinaemia. Pediatr Infect Dis J 1988; 7: S92-S96.
13. Alcock GS, Liley H. Systematic review: immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002; CD003313
14. Gottstein R, Cooke RW. Systemic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2003; 88: F6-F10. (Pubitemid 36084200)
15. Management of hyperbilirubinaemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297.
16. Ferguddon D, Hutton B, Sharma M. et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005; 45: 1640-1657.
17. Hughes RA, Raphael JC, Swan AV, et al. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Systematic Rev 2004: CD 002063
18. Berger M, Cupps T, Fauci A. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980; 93: 55-56. (Pubitemid 10072004)
19. Thomas M, Brennan VM, Chap, et al. Rapid subcutaneous immunoglobulin in children. Lancet 1993; 342: 1432-1433.
20. Gardulf A, Andersen V, Bjorkander, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345: 365-369.
21. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96: 1474-1478. (Pubitemid 47416445)
22. Waniewski J, Gardul A, Hammarstom L, Bioavailability of gammagobulin after subcutaneous infusion in patients with common variable immunodeficiency. J Clin Immunol 1994; 14: 90-97. (Pubitemid 2081020)
23. Berger M. Subcutaneous immunoglobulin replacement in primary immunoglobulin replacement in primary immunodeficiency. Clin Immunol 2004; 112: 1-7.
24. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26: 265-273. (Pubitemid 43901655)
25. Chapel HM, Spickett GP, Ericson D. et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20: 94-100. (Pubitemid 30314313)
26. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17: 241-251. (Pubitemid 37310931)
27. Australian Health Ministers Advisory Council. Review of the use and supply of intravenous immunoglobulin in Australia. A report by the Blood and Blood Products Committee. June 2000. htpp://www.nba.gov.au/pubs/-pdf.ivig.pdf (last accessed: 15 February 2008).
28. Vo AA, Cam Vi, Toyada M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single center experience. Clin J Am Soc Nephrol 2006; 1: 844-852.